Key result
Percutaneous autologous skeletal myoblast transplantation shows therapeutic potential in post-infarction heart failure.
Why the study?
Cell therapy using autologous skeletal myoblasts is being explored to restore myocardial contractile performance after infarction injury, especially in fibrotic post-infarction scars without viable myocardium.
Cell therapy remains investigational post-MI; leaves open myoblast utility in nonviable scar.
Cell therapy may be a potentially attractive approach to restore myocardial contractile performance after an infarction injury. Multipotent stem cells are currently being studied as a possible cell source for myocardial repair within the first few days after the infarction onset in non-revascularizable areas of the left ventricle having viable myocardium. In the presence of fibrotic post-infarction scar with no detectable myocardial viability, direct myocyte precursors, i.e. myoblasts, are being considered as a potential source of new muscle fibres. We review the current clinical experience with transplantation of the autologous skeletal myoblasts in patients with post-infarction heart failure, focusing on percutaneous cell transplantations performed as a sole procedure.
No takes yet. Share an insight, caveat, or question.
Siminiak et al. (2006) conducted a review in Post-infarction heart failure. Percutaneous transplantation of autologous skeletal myoblasts was evaluated. This review summarizes the current clinical experience with percutaneous transplantation of autologous skeletal myoblasts performed as a sole procedure in patients with post-infarction heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: